Thermo Fisher Scientific Announces Offering Of Senior Notes

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it intends to offer senior notes to fund its acquisition of One Lambda and for other general corporate purposes. The One Lambda acquisition was announced by the company on July 16, 2012, for an aggregate purchase price of approximately $925 million.

The joint book-running managers for the offering are Goldman, Sachs & Co., J.P. Morgan Securities LLC and RBS Securities Inc.

Thermo Fisher has filed a registration statement on Form S-3 (including a prospectus) with the Securities and Exchange Commission (the “SEC”) for this offering. Prospective investors should read the prospectus forming a part of that registration statement and the preliminary prospectus supplement related to the offering and the other documents that the company has filed with the SEC for more complete information about the company and this offering. These documents are available at no charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, these documents will be made available upon request by the company or by any underwriter or dealer participating in the offering. Interested parties may obtain a prospectus or the related preliminary prospectus supplement from Goldman, Sachs & Co. by directing a request to 200 West Street, New York, NY 10282, Attn: Prospectus Department, or by calling 866-471-2526; from J.P. Morgan Securities LLC by directing a request to 383 Madison Avenue, New York, NY 10179, Attn: High Grade Syndicate Desk – 3rd Floor, or by calling 212-834-4533; or from RBS Securities Inc. by directing a request to 600 Washington Boulevard, Stamford, CT 06901, Attn: Debt Capital Markets Syndicate, or by calling 866-884-2071.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes, nor shall there be any offer, solicitation or sale of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

Copyright Business Wire 2010

If you liked this article you might like

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Big Pharma and the Sellers of Its Products Now Have a Problem

Big Pharma and the Sellers of Its Products Now Have a Problem

Jim Cramer: The 3 Best Sectors That Lifted the Stock Market

Jim Cramer: The 3 Best Sectors That Lifted the Stock Market

Cramer: Lessons From the Market and ICR

Cramer: Lessons From the Market and ICR